文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

托珠单抗治疗住院COVID-19患者细胞因子释放综合征:生存与临床结局

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
PubMed 文献 · Chest · 2020-06-15
一句话结论观察性研究显示,以托珠单抗靶向CRS的治疗算法可能影响机械通气和生存结局,但需随机试验证实。

该观察性研究纳入2020年3月10日至3月31日连续住院的239例COVID-19患者,随访至2020年4月21日,采用病历回顾,按入院时疾病严重程度(严重:需≥3 L/min补充氧气维持血氧饱和度>93%)分层,报告14天生存和机械通气结局。153例(64%)接受托珠单抗治疗,其中严重疾病患者占90%。严重疾病与较低生存率(78% vs 93%;P<.001)、更高机械通气比例(44% vs 5%;P<.001)和更长中位机械通气天数(5.5 vs 1.0;P=.003)相关。接受托珠单抗的严重疾病患者生存率与非严重疾病患者相似(83% vs 91%;P=.11);需要机械通气的托珠单抗治疗患者生存率为75%(95%CI,64-89)。治疗后氧合和炎症生物标志物改善,但D-二聚体和可溶性IL-2受体水平显著升高。

要点

  • 严重疾病(入院时需≥3 L/min补充氧气维持血氧饱和度>93%)与较低生存率(78% vs 93%;P<.001)和更高机械通气比例(44% vs 5%;P<.001)相关。
  • 153例(64%)接受托珠单抗治疗,其中90%为严重疾病患者;44%的非严重疾病患者因进展性CRS接受托珠单抗。
  • 接受托珠单抗的严重疾病患者生存率与非严重疾病患者相似(83% vs 91%;P=.11)。
  • 接受托珠单抗且需要机械通气的患者生存率为75%(95%CI,64-89)。
  • 托珠单抗治疗后氧合和炎症生物标志物改善,但D-二聚体和可溶性IL-2受体水平显著升高。

适用人群与场景

  • 2020年3月10日至3月31日连续住院的COVID-19患者,随访至2020年4月21日。
  • 按入院时疾病严重程度分层:严重疾病定义为需≥3 L/min补充氧气维持血氧饱和度>93%。

诊断标准与关键阈值

  • 严重疾病:入院时需≥3 L/min补充氧气维持血氧饱和度>93%。

处置流程与药物剂量

  • 使用针对CRS的治疗算法,其中包括托珠单抗;具体剂量、给药途径和频次原文未提及。

研究设计与关键结果

  • 研究类型:观察性研究,连续纳入239例住院COVID-19患者,通过病历回顾进行。
  • 中位年龄64岁;黑人和西班牙裔分别占36%和19%。
  • 严重疾病与较低生存率(78% vs 93%;P<.001)、更高机械通气比例(44% vs 5%;P<.001)和更长中位机械通气天数(5.5 vs 1.0;P=.003)相关。
  • 153例(64%)接受托珠单抗治疗,其中90%为严重疾病患者;44%的非严重疾病患者因进展性CRS接受托珠单抗。
  • 接受托珠单抗的严重疾病患者入院时高敏C反应蛋白较高(120 vs 71 mg/L;P<.001)且更早接受托珠单抗(2 vs 3天;P<.001),但生存率与非严重疾病患者相似(83% vs 91%;P=.11)。
  • 接受托珠单抗且需要机械通气的患者生存率为75%(95%CI,64-89)。
  • 托珠单抗治疗后不良事件少,氧合和炎症生物标志物(如高敏C反应蛋白、IL-6)改善;但D-二聚体和可溶性IL-2受体(又称CD25)水平显著升高。
  • 控制年龄后,黑人和西班牙裔患者的生存率显著高于白人患者(log-rank检验,P=.002)。

证据类型、等级与局限

  • 证据类型:观察性研究(病历回顾)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,包含托珠单抗靶向CRS的治疗算法可能影响机械通气和生存结局。
  • 作者认为,接受托珠单抗的患者氧合和炎症生物标志物改善,生存率高于预期。
  • 作者认为,随机试验必须证实这些发现。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Tocilizumab, an IL-6 receptor antagonist, can be used to treat cytokine release syndrome (CRS), with observed improvements in a coronavirus disease 2019 (COVID-19) case series.

RESEARCH QUESTION: The goal of this study was to determine if tocilizumab benefits patients hospitalized with COVID-19.

STUDY DESIGN AND METHODS: This observational study of consecutive COVID-19 patients hospitalized between March 10, 2020, and March 31, 2020, and followed up through April 21, 2020, was conducted by chart review. Patients were treated with tocilizumab using an algorithm that targeted CRS. Survival and mechanical ventilation (MV) outcomes were reported for 14 days and stratified according to disease severity designated at admission (severe, ≥ 3 L supplemental oxygen to maintain oxygen saturation > 93%). For tocilizumab-treated patients, pre/post analyses of clinical response, biomarkers, and safety outcomes were assessed. Post hoc survival analyses were conducted for race/ethnicity.

RESULTS: Among the 239 patients, median age was 64 years; 36% and 19% were black and Hispanic, respectively. Hospital census increased exponentially, yet MV census did not. Severe disease was associated with lower survival (78% vs 93%; P < .001), greater proportion requiring MV (44% vs 5%; P < .001), and longer median MV days (5.5 vs 1.0; P = .003). Tocilizumab-treated patients (n = 153 [64%]) comprised 90% of those with severe disease; 44% of patients with nonsevere disease received tocilizumab for evolving CRS. Tocilizumab-treated patients with severe disease had higher admission levels of high-sensitivity C-reactive protein (120 vs 71 mg/L; P < .001) and received tocilizumab sooner (2 vs 3 days; P < .001), but their survival was similar to that of patients with nonsevere disease (83% vs 91%; P = .11). For tocilizumab-treated patients requiring MV, survival was 75% (95% CI, 64-89). Following tocilizumab treatment, few adverse events occurred, and oxygenation and inflammatory biomarkers (eg, high-sensitivity C-reactive protein, IL-6) improved; however, D-dimer and soluble IL-2 receptor (also termed CD25) levels increased significantly. Survival in black and Hispanic patients, after controlling for age, was significantly higher than in white patients (log-rank test, P = .002).

INTERPRETATION: A treatment algorithm that included tocilizumab to target CRS may influence MV and survival outcomes. In tocilizumab-treated patients, oxygenation and inflammatory biomarkers improved, with higher than expected survival. Randomized trials must confirm these findings.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Price CC, Altice FL, Shyr Y, et al. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes. Chest. 2020. PMID: 32553536. doi:10.1016/j.chest.2020.06.006

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。